

# Moussab Damlaj

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1593492/publications.pdf>

Version: 2024-02-01

72  
papers

675  
citations

687363

13  
h-index

610901

24  
g-index

72  
all docs

72  
docs citations

72  
times ranked

1421  
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome. <i>Bone Marrow Transplantation</i> , 2022, 57, 292-294.	2.4	1
2	Feasibility of early sirolimus cessation post non-myeloablative transplantation in adult patients with severe sickle cell disease. <i>Bone Marrow Transplantation</i> , 2022, 57, 319-322.	2.4	1
3	Identification of Offspring Donors in Regions of High Consanguinity: New Prospects for Donor Procurement. <i>Transplantation Proceedings</i> , 2022, 54, 593-593.	0.6	0
4	Rates and predictors of infusion-related reactions in patients receiving standard versus prolonged infusion of rabbit anti-thymocyte globulin for hematopoietic stem cell transplantation, a retrospective analysis. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0
5	Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 215-227.	6.0	160
6	Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e66-e75.	0.4	22
7	Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience. <i>Leukemia Research Reports</i> , 2021, 15, 100240.	0.4	3
8	Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. <i>British Journal of Haematology</i> , 2021, 192, 761-768.	2.5	41
9	Outcome of Middle East Respiratory Syndrome (MERS) in hematology and oncology patients: A case series in Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2021, 14, 353-357.	4.1	0
10	Reducing Futile Acute Care Services for Terminally Ill Patients With Cancer: The Dignity Project. <i>JCO Oncology Practice</i> , 2021, 17, e1794-e1802.	2.9	6
11	Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East. <i>Bone Marrow Transplantation</i> , 2021, 56, 2144-2151.	2.4	16
12	A retrospective evaluation of the value of COVID-19 screening and testing in patients with cancer: Aiming at a moving target. <i>Journal of Infection and Public Health</i> , 2021, 14, 949-953.	4.1	4
13	Infectious complications in adult sickle cell anemia patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 3078-3080.	2.4	1
14	Prevalence, Risk Factors, and Outcomes of Platelet Transfusion Refractoriness in Critically Ill Patients: A Retrospective Cohort Study. <i>Critical Care Research and Practice</i> , 2021, 2021, 1-11.	1.1	3
15	Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era. <i>Leukemia Research Reports</i> , 2021, 16, 100276.	0.4	0
16	Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. <i>Current Research in Translational Medicine</i> , 2020, 68, 131-137.	1.8	3
17	Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 690-696.	0.4	1
18	Expression of Immune Response Markers in Arab Patients With Lung Cancer. <i>JCO Global Oncology</i> , 2020, 6, 1218-1224.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplantation, 2020, 55, 2322-2325.	2.4	4
20	A Prospective Survey of Outpatient Medication Adherence in Adult Allogeneic Hematopoietic Stem Cell Transplantation Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 1627-1634.	2.0	20
21	Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review. Leukemia Research Reports, 2020, 14, 100206.	0.4	7
22	Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review. Hematology/ Oncology and Stem Cell Therapy, 2020, 14, 252-256.	0.9	15
23	Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature. Journal of Medical Case Reports, 2020, 14, 54.	0.8	5
24	Reducing futile acute care services (ACS) for terminally ill cancer patients (Dignity Project).. Journal of Clinical Oncology, 2020, 38, 23-23.	1.6	1
25	Expression of immune response markers in Arab patients with lung cancer.. Journal of Clinical Oncology, 2020, 38, e21543-e21543.	1.6	0
26	Validation of the International Prognostic Index and Subsequent Revisions for Diffuse Large B-Cell Lymphoma in Patients From the Middle East and North Africa Region. Cureus, 2020, 12, e9620.	0.5	2
27	Cluster of Differentiation 20 Expression and Rituximab Use Do Not Improve Outcome of Classical Hodgkin Lymphoma Patients. Blood, 2020, 136, 26-27.	1.4	0
28	Favourable Outcome of Non Myeloablative Allogeneic HSCT in Adult Patients with Severe Sickle Cell Disease: A Single Center Experience of 110 Patients. Blood, 2020, 136, 1-2.	1.4	1
29	BCL-2 overexpression overcomes cell of origin stratification in diffuse large B-cell lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 174-177.	0.9	3
30	Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. Blood Reviews, 2019, 33, 63-73.	5.7	38
31	Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease. Journal of Hematopathology, 2019, 12, 157-162.	0.4	1
32	Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e559-e563.	0.4	13
33	Isolated Bone Marrow Non-Langerhans Cell Histiocytosis Preceding RUNX1-Mutated Acute Myeloid Leukemia: Case Report and Literature Review. American Journal of Clinical Pathology, 2019, 151, 638-646.	0.7	5
34	12...Outpatient follow-up is associated with reduced emergency department visits in patients with sickle cell disease: a retrospective cohort study from riyadh, saudi arabia. , 2019, , .		0
35	HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma. Current Research in Translational Medicine, 2019, 67, 31-33.	1.8	2
36	Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e71-e79.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1168-1172.	2.4	12
38	Detection of secondary malignancy following high-dose chemotherapy in germ cell tumors: prospects and limitations. <i>Bone Marrow Transplantation</i> , 2018, 53, 661-663.	2.4	0
39	Limited role of bone marrow biopsy for detection of marrow involvement in patients with Hodgkin lymphoma from the Middle East and North Africa region. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 114-117.	0.9	0
40	Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. <i>Leukemia and Lymphoma</i> , 2018, 59, 739-742.	1.3	11
41	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. <i>Systematic Reviews</i> , 2018, 7, 144.	5.3	15
42	Peripheral hematopoietic stem cell mobilization utilizing growth factors in donors with sickle cell trait is safe and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1366-1368.	2.4	3
43	Guide lines for management of adult histiocytic disease. <i>Journal of Applied Hematology</i> , 2018, 9, 111.	0.3	2
44	Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma. <i>World Journal of Transplantation</i> , 2018, 8, 252-261.	1.6	3
45	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1478-1484.	2.0	31
46	Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2019-2020.	2.0	0
47	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. <i>Leukemia and Lymphoma</i> , 2017, 58, 872-881.	1.3	29
48	Lymphocyte recovery is an independent predictor of relapse in allogeneic hematopoietic cell transplantation recipients for acute leukemia. <i>World Journal of Transplantation</i> , 2017, 7, 235.	1.6	2
49	A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1279-1286.	2.4	12
50	Vancomycin-resistant <i>Enterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transplant Infectious Disease</i> , 2016, 18, 913-920.	1.7	40
51	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1431-1439.	2.0	26
52	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. <i>Transfusion</i> , 2016, 56, 518-527.	1.6	14
53	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4593-4593.	1.4	0
54	Role of FDG-PET/CT for Detection of Occult Bone Marrow Involvement in Patients from the Middle East and North Africa Region with Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 5348-5348.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Prognostic Impact of Blood Count Recovery Based Complete Remission Prior to Allogeneic Transplantation in Patients with Acute Leukemia. <i>Blood</i> , 2016, 128, 5787-5787.	1.4	0
56	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 699-704.	0.4	11
57	Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?. <i>Leukemia and Lymphoma</i> , 2015, 56, 6-7.	1.3	1
58	Comparative Analysis of Azacitidine and Decitabine in Myelodysplastic Syndromes: A Systematic Review and Network Meta-Analysis. <i>Blood</i> , 2015, 126, 1692-1692.	1.4	2
59	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 3210-3210.	1.4	1
60	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. <i>Blood</i> , 2015, 126, 736-736.	1.4	2
61	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. <i>Blood</i> , 2015, 126, 5260-5260.	1.4	0
62	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4980-4980.	1.4	0
63	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490.	1.4	0
64	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. <i>Blood</i> , 2015, 126, 4910-4910.	1.4	0
65	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1913-1913.	1.4	0
66	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993.	1.4	0
67	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. <i>Blood</i> , 2015, 126, 4370-4370.	1.4	0
68	Refractory autoimmune hemolytic anemia in a patient with DiGeorge syndrome treated successfully with plasma exchange: a case report and review of the literature. <i>International Journal of Hematology</i> , 2014, 100, 494-497.	1.6	12
69	Hepatic ALECT-2 Amyloidosis Causing Portal Hypertension and Recurrent Variceal Bleeding. <i>American Journal of Clinical Pathology</i> , 2014, 141, 288-291.	0.7	18
70	A Case Of Refractory Autoimmune Hemolytic Anemia In a Patient With Digeorge Syndrome Treated Successfully With Plasma Exchange. <i>Blood</i> , 2013, 122, 4829-4829.	1.4	0
71	Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center. <i>Blood</i> , 2013, 122, 5186-5186.	1.4	1
72	Phage Display Reveals Multiple Contact Sites between FhuA, an Outer Membrane Receptor of <i>Escherichia coli</i> , and TonB. <i>Journal of Molecular Biology</i> , 2006, 357, 236-251.	4.2	40